SubjectWell Announces Marketplace Expansion into Oncology Clinical Trials
The company has added clinical trial options for patients with non-small cell lung cancer
AUSTIN, TX, March 16, 2022 – SubjectWell, the risk-free clinical trials marketplace for patient recruitment, announced today it has expanded its services to include oncology clinical trials, beginning with non-small cell lung cancer (NSCLC). The company is leveraging its proven clinical trial marketplace, which has been used to reach patients across more than 175 therapeutic areas, to provide unparalleled access for patients at various stages of their NSCLC diagnosis and offer the consistent support needed throughout the clinical trial process.
NSCLC is the most common lung cancer, accounting for about 85 percent of all lung cancer cases, according to the American Cancer Society. SubjectWell’s expansion into oncology clinical trials comes at a time when cancer patients, specifically those with NSCLC, are looking for emerging treatments but are often hindered by a complex clinical trial process.
“The healthcare industry has seen a substantial increase in oncology trials over the past 10 years. However, despite this increase, awareness of trials as a viable care option remains low. Plus, these types of studies have notoriously complicated protocols and greater time sensitivity, making patient recruitment much more difficult. It’s no surprise that, as stated by Applied Clinical Trials, less than 5 percent of eligible adults participate in clinical trials for oncology, said Ivor Clarke, CEO of SubjectWell. “However it’s not for a lack of interest – there’s a common perception that oncology patients won’t consider clinical trials because they rely exclusively on the recommendations of their caregivers, but we’ve already seen more than 40,000 cancer patients register into our expanded marketplace specifically looking for new treatment options. With SubjectWell’s patient-centric model, we’re uniquely positioned to meet the needs of patients who are eager to participate in clinical research with more support.”
With a risk-free marketplace primed with registered NSCLC patients searching for care options, SubjectWell is poised to accelerate enrollment for the more than 200 current and upcoming NSCLC clinical trials. Looking forward, the company will continue its expansion into oncology, adding more indications and covering new regions.
To learn more about SubjectWell, visit www.subjectwell.com, or if interested in including an NSCLC trial in SubjectWell’s risk-free marketplace, email email@example.com for a risk-free recruiting assessment.
SubjectWell, the risk-free clinical trials marketplace for patient recruitment, is raising awareness of clinical research in the general population and providing patients more choice and easy access to innovative treatment options. Visit SubjectWell.com to find out more.
Crowley Webb for SubjectWell